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  Xenobiotic metabolism is an important process within the human body, as 
it alters large, foreign, hydrophobic molecules and prepares them for excretion.  
This process is largely carried out in the liver and is accomplished by a 
superfamily of heme-containing enzymes, termed the Cytochrome P450’s.  Each 
individual P450 has a certain specificity for the substrates it may metabolize, but 
these enzymes are non-selective in nature and may catalyze the metabolism of a 
wide variety of substrates.  Due to this characteristic of P450 – mediated 
metabolism, pharmaceuticals when taken concomitantly may possibly interfere 
with one another’s metabolism, which can lead to adverse drug reactions.  This 
can also be true for natural product constituents that have been consumed as a 
part of one’s dietary intake.  Consumption of the aҫai berry (Euterpe oleracea) 
has grown quite rapidly in recent years as it contains a high concentration of 
antioxidant molecules, and has also been marketed as a weight loss supplement.  
Although it appears to benefit one’s health and longevity, the aҫai berry has not 
been characterized in terms of its effect on P450 – mediated metabolism.  
Utilizing an activity guided fractionation scheme, aҫai berry extracts were 
assayed in CYP1A1 and CYP1A2 enzyme reactions to determine constituents 
responsible for enzyme inhibition. 
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CHAPTER I 
 
INTRODUCTION 
 
 
1.1.0 Xenobiotic Metabolism 
 
 Xenobiotic metabolism is a vital process within a living organism, as it 
methodically alters any consumed, foreign molecules and prepares them for 
excretion.  These molecules can be either large or small, polar or non-polar, and 
toxic or non-toxic.  This process often involves the oxidation of non-polar species, 
which renders them slightly more polar and soluble in water.  These compounds 
may be ingested via a variety of vectors such as pharmaceuticals, constituents 
consumed from one’s daily dietary intake, or exposure to environmental 
pollutants1.  It is of utmost physiological importance to eliminate these exogenous 
compounds from the human body, as high systemic concentrations may lead to 
deleterious or even life – threatening side effects2.  Degradation of these 
compounds is accomplished by two different phases.   
 Phase I metabolism is largely carried out by a superfamily of heme – 
containing enzymes named the Cytochromes P450.  The heme, which is located 
in the active site of these enzymes, is able to bind and activate molecular oxygen 
to react with a substrate molecule.  These enzymes are characterized as 
monooxygenases, and a general monooxygenase reaction can be seen in 
Equation 1.  Although there is some specificity as to what substrates a certain 
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CYP enzyme will metabolize, these enzymes are non – selective in nature and 
can interact with a plethora of different molecules3.  The duration of a foreign 
molecule’s clearance from the body is majorly affected by the rate at which one 
or more CYP enzymes catalyze its degradation4.  Metabolites generated from 
phase I metabolism are generally polar and are excreted via the renal system, as 
polar molecules typically do not bind with plasma proteins in the blood and are 
filtered out within the kidney5. 
 Phase II metabolism involves the conjugation of xenobiotics or their 
metabolites, oxidative byproducts, or toxic species to biomolecules such as 
glucose, sulfate, or glutathione4.   This phase of the pathway is responsible for 
neutralizing chemical species that the body does not recognize as an 
endogenous compound.  Metabolites formed as a result of phase II metabolism 
are conjugated, which results in an increased molecular weight, as well as 
polarity.  A common route of elimination for these compounds is via the 
intestines.  These compounds are excreted by the liver into bile found within the 
gallbladder; once contained in the bile, they are secreted into the intestinal tract 
and eliminated in the feces.  However, some enzymes located in the intestinal 
flora are capable of hydrolyzing certain glucuronide or sulfate conjugates, which 
in result releases the less-polar compound, and renders it available for 
reabsorption.  This process is known as enterohepatic circulation, and prolongs 
the lifetime of the xenobiotic within the body5. 
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RH + O2 + NADPH → ROH + H2O + NADP+ 
 
Equation 1. General Reaction of Cytochrome P450. 
 
 
1.2.0 Cytochrome P450’s 
 
A large portion of these drug – metabolizing enzymes belong to the 
Cytochrome P450 superfamily, which were first identified within the endoplasmic 
reticulum of hepatocytes by J. Axelrod and B. Brodie et al., in 19556,7.  They form 
a class of ubiquitous, membrane – bound enzymes, which are found in either 
cellular endoplasmic reticulum or mitochondrial membranes, and are present 
throughout many forms of life8.  The term P450 corresponds to the unique 
absorption spectrum observed when the enzyme is complexed with carbon 
monoxide; first demonstrated in 1958 by Garfinkle using pig liver, and 
Klingenberg using rat liver, the CO complexed enzyme displays a maximum 
absorbance when exposed to a wavelength of 450 nm9,10. 
Within this superfamily of enzymes, there are many individual enzymes, 
which are termed isozymes.  Although isozymes may have many characteristics 
in common, minute differences in their genomic or amino acid sequence, 
substrates that they may metabolize, and their three – dimensional structure give 
rise to the unique properties of an individual enzyme11.  Isozymes are named 
using a three character identification system followed after the CYP abbreviation, 
which is classified based on genome sequence homology.  For example, 
CYP1A1, would denote that this isozyme belongs to the ‘1’ family, the ‘1A’ 
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subfamily, and the final ‘1’ refers to the specified enzyme species within that 
subfamily. 
1.2.1 Cytochrome P450 Active Site And Catalytic Cycle 
One highly conserved feature of CYP450 enzymes is their heme – 
containing active site, which is essential in the oxidative catalysis of CYP450 
substrates12.  This ‘heme’ is a porphyrin molecule containing an iron atom, which 
is located within the center of the structure.  Below in Figure 1 shows several of 
the oxidative species involved in CYP450 enzymatic reactions; the ferric iron 
center is able to activate molecular oxygen (O2) via a method shown below in 
Figure 2.  Displacement of an active site water molecule by a substrate molecule, 
RH, is the initial step in this process (1).  The ferrous iron center gains an 
electron, which reduces it to the ferrous state (2) capable of binding to molecular 
oxygen (3).  A newly formed iron-oxo radical is further reduced by addition of 
another electron (4).  An oxygen atom is then protonated generating a water 
molecule, which leaves the active site and creates a double bond between the 
remaining oxygen atom and the iron center (5).  Through this activation cycle the 
enzyme is able to generate an extremely reactive oxygen species that is capable 
of oxidizing virtually any organic compound13 (6).  Direct binding of a peroxide 
molecule to the unbound ferric center is another possible means of activation 
(2*).  With this being said, CYP450 enzymes are non – selective in nature and 
can catalyze a plethora of reactions, pending the availability of a given substrate 
within an enzyme’s active site14. 
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Figure 1.  Oxidative Species of the CYP450’s15.  The heme iron is able to utilize 
oxygen as a radical (1), nucleophile (2, 3), and electrophile (4). 
 
 
 
 
Figure 2.  Catalytic Cycle of a CYP450 Monooxygenase Reaction.  This cycle is 
thought to be conserved in nearly all P450 species. 
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Structural differences that arise from the various genomic sequences of the 
CYP450 superfamily play the ultimate role of allowing different substrates access 
to the various active sites.  Size, shape, and arrangement of functional groups of 
the active site are primarily what give rise to an enzyme’s affinity for a substrate 
molecule16. 
1.2.2 Hydroxylation of Hydrocarbon Molecules 
One of the most basic, as well as most common monooxygenase 
reactions catalyzed by the CYP450’s, is the hydroxylation of a sp3 carbon.  This 
reaction, which is shown below in Figure 3, is a two – step radical mechanism.  
First a hydrogen atom is abstracted by the oxo-ferryl group in the Fe(V) oxidation 
state, which leaves a radical carbon of where the hydrogen was abstracted17.  A 
step termed “oxygen rebound” happens immediately following the hydrogen 
abstraction, as the hydroxyl group on the heme transfers to the formed radical 
carbon.  A hydroxylated product is formed from this reaction, and returns the 
enzyme back to its resting ferric state17. 
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Figure 3.  Hydrocarbon Hydroxylation Reaction.  Primary reaction of CYP450 
enzymes, using a two-step radical mechanism. 
 
 
1.2.3 Heteroatom Dealkylation 
Substrates involving a target carbon located adjacent to a nitrogen, 
oxygen, or sulfur typically undergo CYP450 mediated hydroxylation, and results 
in the oxidation and dealkylation of the substrate.  This reaction is important as 
the substrate probe used in both 1A1 and 1A2 enzyme reactions, is an ether 
molecule.  Shown in Figure 4 is the accepted mechanism of this reaction.  Due to 
the proximity of the newly added hydroxyl group to the adjacent heteroatom, the 
product molecule undergoes an intramolecular reaction that results in the 
formation of the final product, as well as a secondary metabolite, which is usually 
an aldehyde molecule18. 
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Figure 4.  Dealkylation of Heteroatom Molecules.  Hydrogen abstraction followed 
by oxygen rebound, resulting in the product of interest (ROH) and a formaldehyde 
molecule. 
 
 
1.3.0 Kinetics of Cytochrome P450 – Mediated Drug Metabolism 
Using the Michaelis – Menten model of enzyme kinetics it is possible to 
relate the velocity of an enzymatic reaction to the concentration of substrate 
present.  Upon substrate (S) binding to an enzyme’s active site (E), an enzyme – 
substrate complex (ES) is created.  This complex undergoes catalysis to yield a 
product, as well as a regenerated enzyme.  The rates at which these steps take 
place while the reaction is at “steady – state,” allows the prediction of important 
physical parameters such as the Km and Vmax.  An equation that is representative 
of this concept is shown as follows in Equation 2: 
 
v = (VMax [S]) / (Km + [S]) 
 
Equation 2.  Michealis – Menten Model of Enzyme Kinetics Equation. 
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This equation is plotted along an XY axis that is shown in Figure 5 and 
follows a rectangular hyperbolic relationship, which appears roughly linear at low 
substrate concentrations, but asymptotically approaches a maximum velocity 
(Vmax).  This Vmax term reflects conditions at which an enzyme is at its maximum 
rate of product formation, due to the complete saturation of the enzymes with 
substrate.  The substrate concentration at which the velocity of the enzymatic 
reaction is 50% of its maximum is termed the Km and is another important 
constant in Michaelis – Menten kinetics.  At this substrate concentration, 50% of 
enzymes within a reaction have a substrate molecule bound to its active site.  
When developing and optimizing an enzymatic bioassay, it is imperative to use a 
substrate concentration in close proximity to the Km value, as changes in the rate 
of product formation are most apparent under these conditions. 
 
 
 
Figure 5.  Michealis – Menten Plot.  Illustration of the rectangular hyperbolic 
relationship between reaction velocity (V) and substrate concentration [S], also 
shows two important parameters Km and Vmax. 
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1.3.1 CYP450 Inhibition 
 As mentioned previously, CYP450 molecules serve to remove and 
detoxify foreign compounds ingested within the human body2.  As with any 
enzyme, when in the presence of competing substrate molecules or related 
compounds, the activity towards a single substrate is reduced.  The purpose of 
this project is to investigate inhibition of CYP450 isoforms by constituents found 
in the aҫai berry, which has gained much attention as of late for its positive health 
effects19-23.  An enzyme inhibitor is any molecule that decreases an enzyme’s 
efficacy, and alters the metabolism of another molecule’s metabolism.  Inhibition 
can be either a reversible or irreversible process.  Reversible inhibition involves 
an enzyme’s affinity for another substrate molecule, and only lasts as long as the 
inhibitor is present24.  Irreversible inhibition occurs when an inhibiting molecule 
binds covalently to the active site or a key amino acid residue.  Reactive 
metabolites generated from CYP450 catalysis can also affect the enzyme in this 
manner, in a process known as “suicide inhibition,” and will permanently remove 
the affected enzyme from the catalytic enzyme pool.  An equation used to 
calculate KI for competitive inhibition is shown below in equation 3.  In this 
equation the term denoted α is representative of the ratio between the Km value 
observed in a controlled experiment with no inhibitor and the Km app observed in 
experimental reactions.  This value, which can be determined experimentally, is 
equal to the concentration of inhibitor ([I]) divided by Ki, plus 1.  Rearrangement 
11 
 
of the equation to solve for Ki yields a value reflective of the inhibitors binding 
affinity with the enzyme. 
 
α = (Km app / Km) = 1 + ([I] / Ki) 
 
Equation 3.  Ki Determination for a Competitive Inhibitor. 
 
 
1.4.0 Drug Interactions and Adverse Drug Reactions In CYP450 Isoforms 
 It is of considerable interest to study cytochrome P450 interactions due to 
the wealth of both prescription and over the counter medications produced by the 
flourishing pharmaceutical industry.  As healthcare is becoming more attainable 
to the average citizen, there has been an enormous increase in the number of 
prescriptions written every day, and as a result it is not by chance that there has 
been an increase in the number of reported adverse drug reactions25.  
Cytochrome P450 enzymes are non – selective in nature, which means that a 
certain isoform may metabolize a wide variety of substrates of related size, 
structures, or chemical properties26.  In the following sections more detail is given 
about known CYP1A1 and CYP1A2 substrates, as well as some specific 
examples of adverse side effects of CYP1A1 and CYP1A2 mediated drug 
metabolism. 
1.4.1 CYP1A1 
 Cytochrome P450 isoform 1A1 is, for the most part, an extrahepatic 
enzyme, although, it can be expressed within the liver.  CYP1A1 has relevance 
not so much as a drug metabolizer, but rather as a metabolizer of endogenous 
12 
 
substrates and is an important detoxifier of environmental pollutants.  
Environmental pollutants are typically highly nonpolar molecules, and can be 
consumed via inhalation from the air or ingested from foods eaten as part of a 
normal diet.  CYP1A1 is largely studied in works interested in cancer prevention.  
This is because many of CYP1A1’s natural substrates are highly nonpolar and 
unreactive, but once subjected to CYP1A1 mediated metabolism, become much 
more reactive resulting from the addition of the heteroatom function group.  
These newly formed reactive products can attack cellular structures, such as 
DNA, which form DNA adducts that can affect the integrity of the DNA 
sequence26.  This process has been termed “carcinogenesis,” as it is the process 
by which a cancer line can arise.  With this being said, it is of interest to 
potentially inhibit reactions of CYP1A1 in an attempt to impede the generation of 
these highly reactive products.  Depicted below in Table 1, is a list of 
endogenous and exogenous substrates of CYP1A1, as well as some known 
inhibitors. 
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Table 1.  List of Known Substrates and Inhibitors of CYP1A126, 27, 28 
 
 
 
 
1.4.2 CYP1A2 
 Cytochrome P450 isoform 1A2 is largely a hepatic enzyme, and has been 
said to account for approximately 13% of CYP450 enzymes found in the liver29.  
Although this percentage can vary highly among individuals, CYP1A2 is an 
important metabolizer of several known prescription drugs, as well as 
environmental toxins and procarcinogens30.  Recent studies have shown that 
CYP1A2 is more heavily involved in pharmaceutical drug metabolism than 
originally believed to be.  Many of these drugs, such as Zolmitriptan, a selective 
serotonin receptor agonist used to alleviate migraine headaches,31 and Tacrine 
an anticholinesterase used in Alzheimer’s treatments32, are medications 
prescribed for CNS disorders.  In most cases a drug molecule will be 
metabolized by several different CYP450 isoforms, but this is not always the 
case.  It is also of importance to realize that when CYP1A2 is in the presence of 
several of its substrates, these substrates of CYP1A2 can act as competitive 
14 
 
inhibitors of one another via competition to enter the enzyme’s active site33.  
Below in Table 2, is a list of known CYP1A2 substrates and inhibitors. 
 
Table 2.  List of Known Substrates and Inhibitors of CYP1A234.  Strong inhibitors 
are denoted in red, while mild inhibitors are denoted in yellow. 
 
 
 
 
1.4.3 Oxidative Stress 
 Although xenobiotic metabolism has an overall beneficial effect, due to the 
means by which this process occurs (using molecular oxygen as an oxidizing 
agent) metabolism of certain drugs, such as acetaminophen, can generate 
reactive metabolites as by-products of the reaction35.  An accumulation of these 
oxidative species can lead to an imbalanced ratio of antioxidants to oxidants36.  
This imbalance can cause oxidative damage to surrounding cells, through 
reaction of activated metabolites with complex cellular molecules such as, 
nucleotides, proteins, and lipids37, 38.  In other words, Cytochrome P450 enzymes 
in humans can detoxify and eliminate foreign chemicals, but they can also 
convert inert chemical species into toxic metabolic products. 
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1.4.4 CYP1A2 Metabolism of Acetaminophen 
 In the case of acetaminophen, overdose poses a serious threat of 
hepatotoxicity, because the secondary (toxic) route for metabolism becomes 
significant at elevated drug levels.  This compound is a non-steroidal anti-
inflammatory drug (NSAID) that is taken to alleviate fevers, headaches, and other 
minor pains caused by inflammation.  Although it is considered safe at 
therapeutic dosages, an overdose of this drug is extremely toxic to liver cells and 
is a major cause of acute liver failure in the United States39.  A diagram depicting 
the usual route of elimination is shown below in Figure 6.  It has been shown that 
at therapeutic dosages, acetaminophen is mainly eliminated in the liver by 
glucuronidation and sulfation reactions40.  Acetaminophen is also metabolized by 
CYP isoforms 2E1, 1A2, 3A4, and 2D6 41.  P4502E1 mediated metabolism of 
acetaminophen is a direct two electron oxidation, that results in the formation of 
N-acetyl-p-benzoquinone imine (NAPQI), which is an extremely reactive 
metabolite35.  NAPQI is a strong electrophile and is rapidly reduced by GSH into 
an acetaminophen-GSH conjugate.  Upon consumption of a toxic dose of 
acetaminophen, its NAPQI metabolite readily depletes hepatic GSH 
concentrations.  This depletion results in NAPQI covalently binding to 
nucleophilic groups of important cellular proteins42.  Covalent alteration of these 
proteins can cause reduced or impaired activity of necessary cellular functions.  
Depletion of hepatic GSH may also result in an accumulation of peroxides in 
cells, as glutathione peroxidase, a major peroxide detoxification pathway, cannot 
16 
 
proceed without its necessary cofactor GSH39.  Oxidative stress in the cell 
resulting from acetaminophen overdose has also been shown to have an effect 
on mitochondrial permeability transition43, which can also contribute to acute liver 
failure.  Acetaminophen overdose is but one example of how oxidative stress 
produced as a result of drug metabolism can cause localized tissue damage.  
Although this case is one of the more severe and thus most studied incidents of 
drug induced hepatotoxicity, metabolism of other drug compounds may cause 
milder conditions of oxidative stress.  Over time, exposure to elevated levels of 
oxidants and ROS can cause chronic liver inflammation. 
 
 
Figure 6.  CYP450 Catalysis of Acetaminophen Followed by Phase II Conjugation.  
Usual degradation under physiological conditions and low doses of 
acetaminophen. 
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1.4.5 CYP1A1 Bioactivation of Procarcinogens 
 Acquisition of many forms of cancer have been associated with exposure 
to environmental pollutants, via inhalation and even consumed within one’s diet.  
Much is known of the mechanisms underlying cancer initiation, as well as many 
chemicals that can be responsible (carcinogens).  A large portion of these 
carcinogens are aldehydes or other volatile organic compounds44.  Two other 
classes of carcinogens are the polycyclic aromatic hydrocarbons (PAH), such as 
benzo[a]pyrene, and the tobacco specific nitrosamines (TSN), such as 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone; which are debatably the two of the 
most important compounds in lung carcinogenesis45. 
 As with any foreign, hydrophobic, compound that enters the body via the 
gastrointestinal tract, it is subject to first pass metabolism by the CYP enzymes1.  
Despite that many PAHs are not considered actual carcinogens, CYP oxidation 
of these compounds often results in the formation of reactive products.  Under 
usual circumstances these metabolites are eliminated from the body by phase II 
processes, largely by forming glutathione complexes3.  However, when 
concentrations of glutathione are depleted electrophilic intermediates covalently 
bind to DNA forming adducts which may cause mutations within the genome.  
Over time damaged DNA is unable to be repaired and the sequence becomes 
increasingly replicated, leading to tumorgenesis26.  Since it is the CYP 
metabolism of PAHs that is responsible for the generation of a reactive product, 
inhibition of certain CYP isozymes that are known to catalyze these reactions 
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appears to be a logical approach to ameliorate DNA damage that may ultimately 
lead to cancer.  Isoforms known to activate carcinogens include mainly CYP1A1, 
but CYP1A2 has also been shown to be involved in this process. 
1.5.0 Natural Products and CYP450’s 
It is well known that natural products can have beneficial health effects, 
and there is considerable interest in antioxidant properties of many of these 
products.  The origins of the medicinal use of these natural products can often be 
traced back thousands of years, as herbal products were mainly used in 
traditional medicine.  Through the process of trial and error, indigenous 
civilizations experimented with the local plants to determine the medicinal effect 
that they might have.  With the rise of modern medicine and biochemical 
research during the past two or three decades, techniques have been developed 
to distinguish medicinally active compounds and unravel their complex molecular 
mechanisms.  Much effort has been focused on natural products due in part to 
successful accounts of folklore medicine, but largely because the synthesis of 
medicinally active constituents is “programmed” within a species’ genome, and 
was possibly critical to its survival, as it has been evolutionarily conserved. 
During recent years herbal products have gained increasing popularity, as 
they can prove beneficial to one’s health in numerous ways.  In 2005, it was 
reported by Tindle et al. that 12.1 – 18.6% of adults in the United States used 
herbal remedies46, and this number has only increased in the past ten years as 
these products have been made much more available.  Because herbal drugs 
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are obtained from a natural, plant source, these remedies are often perceived as 
“safe”; but herbal products are a complex mixture of organic constituents, whose 
elimination from the human body is facilitated by the same xenobiotic metabolism 
process as synthetic drugs47.  Despite providing a natural, holistic approach to 
maintaining one’s health and longevity, many of these natural products have not 
been characterized in terms of their effect on CYP450 enzymes and other 
biochemical processes24.  It is of much interest to the healthcare and 
pharmaceutical industries to identify any significant natural product – drug 
interactions, as it is a means to proactively prevent possible adverse drug 
reactions. 
1.5.1 Herbal Drug – Pharmaceutical Drug Interactions 
It has also been shown that certain fruits may interfere with normal drug 
metabolism.  Concomitant intake of herbal products and prescription medication 
was estimated at 16% during the year 200248.  A classic example is the 
interaction of grapefruit with the CYP3A4 isoform.  CYP3A4 is responsible for the 
metabolism of a large percentage of all pharmaceutical drugs24.  It has been 
shown that furanocoumarins found in grapefruit are metabolized by this enzyme 
to generate a reactive metabolite, which then covalently binds to CYP3A4 
causing irreversible inhibition49.  These furanocoumarin constituents are 
specifically bergamottin and 6’,7’-dihydroxybergamottin50, and their 
corresponding structures can be found below in Figure 7.  This interaction is 
significant as drugs taken simultaneously with the consumption of grapefruit may 
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not be fully metabolized and may cause undesirable side effects, or in severe 
cases even drug overdose.  A well – studied example is grapefruit’s interaction 
on the metabolism of statin drugs, which are widely prescribed cholesterol 
modulators51.  Alteration of statin drug metabolism greatly affects these 
medicines’ pharmacokinetic and pharmacodynamics properties, which can cause 
an adverse drug reaction.  Atorvastatin (Lipitor), which is the highest grossing 
drug of all time52, belongs to this class of drugs; so it is imperative that these 
interactions are made known to the pharmaceutical and healthcare industries. 
 
 
 
Figure 7.  Structures of Bergamottin and 6’,7’-Dihydroxybergamottin.  BG (1) and 
DHB (2) are the constituents in grapefruit responsible for CYP3A4 inhibition. 
 
 
1.5.2 Chemopreventative Qualities 
 
A major question within the natural product community throughout the 
1990’s was the biochemical correlation between the relatively high resveratrol 
concentrations found in red wine and the documented cardioprotective effects 
from its consumption; a conundrum termed the “French Paradox”53.  Initial 
research focused on metabolic processes of the cardiovascular system, but it 
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was shown in animal models of carcinogenesis that resveratrol exerts potent 
chemopreventative effects54.  Much research has been geared towards 
understanding the biochemical mechanisms that link together the many ways by 
which resveratrol exerts its chemopreventative, cardiovascular, and 
neuroprotective effects55. 
As mentioned previously, CYP1A1 metabolism of procarcinogenic 
compounds results in the generation of carcinogens.  Upon ingestion of a PAH, it 
binds to the aryl hydrocarbon receptor (AhR), which induces the transcription of 
CYP1A1 proteins in an effort to detoxify the body of these foreign compounds.  
However, this metabolism creates a highly reactive product which is capable of 
covalently binding to DNA, forming DNA adducts that can affect the integrity of 
the DNA sequence26.  Much work has been done evaluating the effects of 
flavonoids and other dietary polyphenols in cell culture models of both cancer 
initiation and promotion55, 56, 57.  In vitro studies investigating flavonoids and other 
polyphenols effect on the cancer initiation stage have shown this class of natural 
products greatly affects many steps necessary for the bioactivation of 
carcinogens and the covalent binding of the carcinogen to DNA58.  This has been 
shown to happen via a variety of different mechanisms; some acting as agonists 
of AhR inducing CYP1A1 transcription, while others may act as antagonists of 
AhR and inhibit the transcription of the bioactivating oxidative enzymes59, 60, 61. 
Although the results of many of these in vitro studies appear promising, 
uncovering a cellular mechanism by which these polyphenols exert their effect 
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has proven to be more complex than originally expected.  Also, in vivo studies 
evaluating the effect of flavonoids and polyphenols have been rather 
disappointing.  This is most likely due to the poor bioavailability of these 
compounds, as they undergo degradation within the gastrointestinal tract and will 
not reach internal organs at a sufficient concentration62, 63.  However, a subclass 
of these polyphenolic compounds, the methoxylated flavones have proven to 
have a considerably greater potential to reach their target tissues compared to 
their unmethylated counterparts.  It has been shown that both 3,4-
dimethoxyflavone and 5,7-dimethoxyflavone can act as an antagonist of AhR, as 
well inhibit the CYP450 bioactivation of benzo[α]pyrene at fairly low 
concentrations (1 – 2 µM)64. 
1.5.3 Aҫai Berry 
There has been a recent increase in the consumption of Aҫai berry, as it is 
widely available in dietary supplements and in some antioxidant drinks.  It is also 
largely marketed as a weight loss supplement, and claims to reduce levels of 
LDL cholesterol65.  Although there have been many reports of beneficial effects, 
the aҫai berry is not yet listed on the U.S. Food and Drug Administration, 
Generally Recognized As Safe (GRAS) list.  This is due to the limited available 
studies in the bioactivity of aҫai berry’s constituents. 
Aҫai berry has been shown to contain a variety of biologically active 
constituents such as hydroxybenzoic acids, antioxidant polyphenolics, flavon-3-
ols, and anthocyanins67.  Aҫai berry juice and pulp has also been examined by 
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another collaborating group here at UNCG, the Cech group.  It was shown by 
their lab that the aҫai berry juice and pulp contains concentrations of anthocyanin 
– class flavonoids, namely cyanidin-3-O-glucoside (C3G) and cyanidin-3-O-
rutinoside (C3R).  After consumption of 18 fl. oz. aҫai berry juice, 
pharmacokinetic analysis of the oral bioavailability show that plasma anthocyanin 
concentrations reach a maximum of 1.1 – 2.3 ng/mL in an average adult.  These 
compounds may be responsible for the antioxidant capabilities of aҫai berry, as 
they are capable of scavenging free – radicals67.  In a study performed by 
Showande et al, a total monomeric anthocyanin value was determined in an 
ethanol extract of Hibiscus sabdariffa, which compared determined ratios of 
individual anthocyanin molecules in the extract to one another.  These 
researchers showed an IC50 value of 306 μg/mL by the anthocyanins on CYP1A2 
mediated metabolism68.  This reported IC50 value is fairly high and physiologically 
irrelevant, which likely means that the anthocyanins found in the aҫai berry 
extracts will not have any effect on the CYP1A2 enzyme.  Despite the somewhat 
related, previous work in this area, there have been no detailed studies 
investigating the effect of aҫai berry constituents on CYP450 detoxifying 
enzymes. 
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1.6.0 Bioassay – Guided Fractionation 
 One of the most common approaches to identifying active constituents in 
natural product research is a method termed bioassay guided fractionation 
(BGF).  This process has shown great effectiveness in identifying medicinally 
active constituents from raw natural product material, as it evaluates the 
pharmacognostic properties of a crude plant extract, which contains an enormity 
of constituents.  This method allows for the separation, isolation, and 
characterization of molecules within a crude mixture that may have physiological 
significance, whether medicinally or toxicologically, in the human body69.  
Paclitaxel, which is a very important chemotherapeutic used in the treatment of 
breast cancer, was discovered in this fashion from screening extracts of 
endophytic fungi found in the Pacific yew tree (Taxus brevifolia)70. 
1.7.0 Objective Statement 
 This project aims to investigate the inhibitory potential of the Amazonian 
aҫai berry (Euterpe olecera) on the Cytochrome P450 isoforms 1A1 and 1A2.  
Currently, there is no published literature demonstrating CYP450 inhibition by the 
aҫai berry.  This project is part of a larger project aiming to investigate inhibition 
of all toxicological significant CYP450 isoforms.  Research completed previously 
shows a modest inhibitory effect by aҫai berry extracts on isoforms 2E1, 2A6, 
and 3A4. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
2.1.0 Preparation of Bioassay Reagents 
2.1.1 Potassium Phosphate Buffer 
 Separate 1 M solutions were prepared from crystalline monobasic and 
dibasic potassium phosphate, which were both purchased from Carolina 
Biological Supply Company.  These solutions were combined to achieve a pH 7.4 
buffer.  This 1 M stock solution of potassium phosphate buffer was stored in a 
refrigerator, and was diluted to a concentration of 100 mM in reaction mixtures.  
Phosphate buffer (10 mM) was also used to dilute the cDNA expressed P450 
isoforms, making them easier to handle during experiments. 
2.1.2 NADPH 
 Nicotinamide adenine dinucleotide phosphate (NADPH), was obtained 
from Chem – Implex International Incorporated in the form of a tetrasodium salt.  
Nanopure water was used to dissolve the NADPH salt to create a 10 mM 
solution, which was partitioned into many smaller fractions.  These stock 
solutions were kept frozen at -80°C until used in CYP450 assays. 
2.1.3 CYP1A1 and CYP1A2 cDNA Expressed Isoforms 
 Specific CYP450 isozymes were acquired from Xenotech INC., and were 
utilized to provide greater certainty that the investigated isoform was solely 
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responsible for product generation.  Upon arrival, enzymes were separated into 
25 µL aliquots, which were stored at -80°C.  Enzymes were removed from the 
freezer, thawed on ice, and diluted tenfold in 10 mM potassium phosphate buffer 
before the enzymatic assay to retain the enzyme’s catalytic activity.  
Concentrations of enzyme used in each reaction varied with regard to the activity 
of the enzyme utilized in each experiment. Enzyme concentration in the 
purchased cDNA expressed CYP450 isoforms was listed at 1 µg/µL. 
2.1.4 Preparation of 7EC Substrate Stock Solution 
A selective substrate of CYP1A1 and CYP1A2 is 7-ethoxycoumarin (7EC), 
which was used to monitor product formation by the enzymes.  Crystalline 7EC 
was purchased from Indofine Chemical Company LLC and was prepared as a 
concentrated, 20 mM stock solution and stored at ≈ -4°C, which was diluted to a 
concentration of 20 μM in each reaction unless otherwise stated.  Since this 
molecule is fairly nonpolar it would not dissolve in water and had to be first 
dissolved in methanol prior to dilution with water.  It is known that too high of a 
methanol concentration can inhibit enzymes, so to avoid this, the amount of 
methanol from the stock substrate was kept at 0.05% or lower in enzymatic 
reactions. 
2.1.5 Aҫai Berry Extracts and Subsequent Fractionations 
 Freeze dried aҫai berry powder was obtained from Optimally Organic LLC.  
The crude plant material was extracted into four different initial solvents, by 
collaborators in Dr. Oberlies’ research group.  Samples received from the 
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Oberlies’ lab were dissolved in solution and partitioned into smaller stock 
solutions, which were dried and refrigerated at 4°C with limited light exposure.  
Preparation of samples for use in CYP450 bioassays involved initial dissolution 
into methanol, which was diluted 100x with nanopure water.  Keeping in mind 
that methanol concentrations may alter an enzymes activity, solvent controlled 
reactions were performed as part of the experiment to ensure enzymes were not 
affected by its presence.  Concentrations of the aҫai berry extracts and fractions 
utilized in different experiments varied tremendously, ranging from 125 ng/mL to 
200 μg/mL in reaction mixtures. 
2.1.6 Preparation of Diosmetin Standard 
 Upon isolation of the compound diosmetin, it was of interest to test pure 
diosmetin in CYP450 enzymatic reactions.  This compound was purchase from 
Indofine Chemical Company Incorporated.  Crystalline diosmetin was initially 
dissolved in 100% DMSO, and diluted with nanopure water accordingly to the 
necessary concentrations needed for reactions. 
2.2.0 Cytochrome P450 Assays 
 A common approach used to investigate enzyme activity is to use an in 
vitro enzymatic bioassay to measure product formation resulting from catalysis.  
Each bioassay consisted of a series of enzymatic reaction mixtures containing 
either CYP1A1 or 1A2 isozyme, phosphate buffer (pH 7.4), 7EC substrate, 
NADPH, and nanopure water to dilute all mixtures to a constant 200 µL volume.  
To ensure that the enzyme was working at its full capability, parameters were 
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evaluated in terms of enzyme concentration and incubation time.  Product 
formation appears to respond linearly when enzyme concentration, and 
incubation times were varied, and the pertaining data can be found in sections 
3.1.1 and 3.1.2 of the results and discussion chapter. 
2.2.1 CYP1A1 Model Assay 
 An in vitro model of CYP1A1 enzyme reactions was achieved by utilizing 
cDNA expressed CYP450 isoforms, and its proposed mechanism is shown in 
Figure 8.  This method allows for the quantification of only products formed via 
CYP1A1 catalysis, which yields more significant, meaningful data.  CYP1A1 is 
largely a metabolizer of endogenous substrates, such as melatonin and 
arachidonic acid26.  A commonly used substrate to investigate CYP1 reactions is 
7-ethoxycoumarin, which is a known anticoagulant.  CYP2 and CYP3 families 
have also been shown to be active catalysts for oxidation of this substrate71.  
However, since only the CYP1A1 isoform is being used, results cannot be 
skewed by product formation from other metabolizers.  The substrate molecule, 
7-ethoxycoumarin, undergoes O-deethylation by CYP1A1 enzymes, which 
results in the production of 7-hydroxycoumarin, more commonly known as 
umbelliferone, along with acetaldehyde. 
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Figure 8. Proposed Mechanism for CYP1A1 O-Deethylation.  Steps showing the 
hydrogen abstraction and oxygen rebound, which result in product 7-
hydroxycoumarin and acetaldehyde. 
 
 
This assay was carried out in 1.5 µL centrifuge tubes containing 20 μM 7-
ethoxycoumarin , 100 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, 
and cDNA expressed CYP1A1 enzymes (5 uµ/mL), in a constant reaction volume 
of 200 µL.  Reactions were initiated upon the addition of NADPH, and incubated 
at 37°C for ten minutes.  After ten minutes, reactions were quenched with 25 µL 
of 70% perchloric acid, and placed on ice to precipitate proteins.  Samples were 
then centrifuged at 15,800 g for eight minutes, and the supernatant was 
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extracted for analysis.  The supernatant was analyzed using HPLC UV/vis 
detection at a wavelength of 320 nm. 
2.2.2 CYP1A2 Model Assay 
 Assays performed to investigate CYP1A2 enzyme activity were very 
similar to the previously mentioned CYP1A1 assays.  As 7-ethoxycoumarin is a 
widely used substrate probe for CYP1 family reactions, this substrate was also 
utilized for CYP1A2 assays71.  However, it was found that this isoform did not 
catalyze the commonly observed O-deethylation reaction seen in other isoforms, 
and the corresponding mechanism is shown in Figure 9.  Instead, it was 
observed that a molecule that eluted later than 7-hydroxycoumarin was the major 
metabolite of the CYP1A2 enzymatic reaction.  Due to the increased retention 
time of this compound, it is believed that CYP1A2 catalyzes an epoxidation 
reaction somewhere on the bicyclic, aromatic ring.  However, it is not known 
exactly where this epoxidation is taking place. 
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Figure 9.  Proposed Mechanism of CYP1A2 Epoxidation.  Due to a more 
hydrophobic molecule observed in 1A2 reactions, an epoxidation is thought to be 
occurring. 
 
 
 Enzymatic assays for this isoform were carried out in 1.5 µL centrifuge 
tubes containing 20 μM 7-ethoxycoumarin, 100 mM potassium phosphate buffer 
(pH 7.4), 1 mM NADPH, and cDNA expressed CYP1A2 enzymes (12.5 µg/mL), 
in a constant reaction volume of 200 µL.  Addition of NADPH was used to initiate 
the reactions, and reactions were incubated at 37°C for ten minutes.  Termination 
of reactions was accomplished by the addition of 25 µL of 70% perchloric acid.  
Samples were immediately placed on ice to precipitate the protein, and spun at 
15,800 g to separate the supernatant from the precipitant.  The supernatant was 
extracted for HPLC UV/vis detection at 320 nm. 
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2.2.3 High Performance Liquid Chromatography (HPLC) 
 HPLC analysis was performed using a Shimadzu LC-20AT, with a UV/vis 
PDA detector.  Analysis of the product 7-hydroxycoumarin molecule was carried 
out using an isocratic mobile phase that consisted of 60% nanopure water, 40% 
acetonitrile, and 0.1% trifluoroacetic acid, and an extended C18 column for the 
stationary phase.  The product showed UV absorbance at 320 nm and a 
retention time of about 3.5 minutes71, 72.  Chromatogram run times were set to ten 
minutes, with the product eluting at about 3.5 minutes and the substrate eluting 
at about 6 to 7 minutes.  Generated product peaks were integrated and used to 
analyze data. 
2.2.4 Data Analysis 
 From the chromatograms that were generated by HPLC analysis, the 
retention time of the product 7-hydroxycoumarin was determined, and the 
corresponding peak was integrated and its area was quantified using the 
Shimadzu computer software.  Acquired peak areas were given arbitrary units 
and are a representation of the assayed enzyme’s activity.  Assays were 
performed in duplicates unless otherwise stated and the reported enzyme activity 
reflects the average of that specified test group. 
2.3.0 Extraction of Aҫai Berry Powder 
 Solvent portioning was used to create four crude aҫai berry extracts, from 
the freeze dried aҫai berry plant material.  This process, which is described in 
Scheme 1, involved the initial dissolution of the crude plant material into a 10:1:9 
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hexane:water:methanol mixture.  Using a separatory funnel, the organic layer 
was extracted from the mixture, which isolated highly lipophilic components, such 
as fatty acids and oils.  This isolate was rationed into smaller samples and dried 
to produce the hexane extracts.  The remaining aqueous methanol layer was 
mixed with chloroform to yield a 4:1:5 chloroform:water:methanol mixture.  Once 
again, the organic phase was extracted, rationed, and dried to generate the 
chloroform extracts.  Addition of butanol to the remaining aqueous phase created 
a 1:1 butanol:water mixture.  Both the butanol and aqueous phases were 
collected separately, rationed, and dried to create the aqueous and butanol 
extracts. 
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Scheme 1.  Flow Diagram of Aҫai Berry Extraction.  Yielded four different extracts 
depending on solvent used. 
 
 
2.3.1 Fractionation of Aҫai Berry Extracts 
 
 A diagram depicting the entire fractionation process throughout this 
process can be found below in Scheme 2.  As described in the previous section, 
four different extracts were generated from the freeze dried aҫai berry plant 
material.  Fractionation of these extracts was performed by our collaborators in 
the Oberlies’ laboratory, at UNCG.  Fractionation of the chloroform extract was 
accomplished with silica-column flash chromatography (RF CombiFlash) using a 
hexane:chloroform:methanol solvent gradient to generate the 34-series fractions.  
Sample 34-8 was selected to be further investigated, and was separated using 
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the same instrument, but used a solvent gradient of hexane:acetone to generate 
the 38-series fractions.  Separation of fraction 38-3 was accomplished using a 
diol column and a solvent gradient of 100% hexane, to 100% ethylacetate, to a 
1:4 ethylacetate:water solution, which created the series termed the 63-series 
fractions.  Fraction 63-4 was chosen for further fractionation using reverse phase 
chromatography with an ISCO C18 column, and a solvent gradient of 1:9 
methanol:water to 100% methanol.  Separation of fraction 63-4 generated the 94-
series fractions, which were high in purity. 
 
 
 
 
 
 
Scheme 2.  Flow Diagram Depicting Entire Bioassay Guided Fractionation of Aҫai Berry Extract.  This scheme 
corresponds to data collected from CYP1A1 enzymatic reactions
36 
37 
 
CHAPTER III 
 
RESULTS AND DISCUSSION 
 
 
3.1.0 Bioassay Development 
 
 In order to measure activities of CYP450 isoforms 1A1 and 1A2, several 
components of each assay were tested in variable quantities.  To optimize these 
assays, variables such as enzyme concentration and incubation time were 
examined.  A linear trend should be observed with increasing incubation time and 
enzyme concentration.  These parameters were investigated to ensure that each 
CYP450 reaction followed typical enzymatic behavior, and to optimize the utilized 
assay prior to the aҫai berry inhibition screening. 
3.1.1 CYP1A1 Model Assay 
 The enzyme reaction using CYP1A1 enzymes was first tested in respect 
to varying incubation times.  It was the goal of this experiment to establish 
linearity between the enzyme’s activity and the time allotted for reactions to 
incubate, as well as determine the optimum time for each performed enzyme 
reaction.  These reactions were performed as described in the previous section.  
Below in Figure 10, a graph can be found displaying the results from this assay.  
Incubation time was varied from 0.0 minutes, to 5.0 minutes, to 10.0 minutes, 
and to 30.0 minutes, and reported activities were measured in arbitrary activity 
units (AU).  A linear trend was observed from 0.0 minutes to 10.0 minutes, with 
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the observed activity at 30 minutes appearing to deviate slightly from the linear 
trend.  This is most likely due to a decrease of enzymatic activity from an 
increased exposure to heating, or a decrease in adequate substrate 
concentrations.  From data collected at 0.0, 5.0, and 10.0 minutes, an R2 value of 
0.9992 was calculated.  It was decided to use an incubation time of ten minutes 
per each enzyme assay. 
 
 
 
Figure 10.  Results Observed from Variation of Incubation Time Using CYP1A1. 
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 Examining the effect of increasing enzyme concentrations was also of 
interest to ensure the assay was working properly, as well as to choose an 
optimum concentration to be used in each assay.  An optimum concentration 
would produce an activity that was sufficient enough to quantitate, keeping in 
mind that during inhibition studies the activity would decrease, but to also be low 
enough to conserve the purchased cDNA expressed enzymes.  Linearity was 
established between enzyme volume and enzymatic activity, which can be seen 
in Figure 11.  Enzyme concentrations of 0.0 µg/mL, 0.5 µg/mL, 1.0 µg/mL, and 
5.0 µg/mL were tested, and each reaction was incubated for ten minutes.  
Enzymatic activity was measured in arbitrary activity units (AU), and it was 
determined that this data fit a linear trend with a R2 value of 0.9998.  It was also 
determined that using a volume of 1 µL of cDNA expressed 1A1 enzymes would 
be sufficient for each reaction. 
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Figure 11.  Results for Variation of Enzyme Concentration With CYP1A1. 
 
 
3.1.2 CYP1A2 Model Assay 
 
 Enzyme reactions using the CYP1A2 were also tested with various 
incubation times.  A linear trend should be observed between an enzyme’s 
activity and incubation time while the enzyme is most active.  It was known that 
too long of an incubation time would cause a decrease in activity, due to 
denaturation or a decrease in substrate availability.  Incubation times were varied 
from 0.0 minutes to 30.0 minutes, and all reaction mixtures were made identical 
to one another.  Results from this experiment were measured in arbitrary activity 
units (AU), and can be found in Figure 12.  Observed data showed a linear trend 
from times 0.0 minutes to 10.0 minutes, with a calculated R2 value of 0.9998.  At 
30.0 minutes the observed activity appeared to deviate from linearity as 
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expected.  As with the CYP1A1 isoform, it was decided that an incubation time of 
10.0 minutes would be an optimum time. 
 
 
 
Figure 12.  Results for Variation of Incubation Times Using the CYP1A2 Isoform. 
 
 
 Effect of increasing cDNA expressed enzyme concentration was also 
examined to ensure enzymes were working properly, and to also choose an 
optimum volume per reaction.  An increasing enzyme concentration should 
directly correlate with the observed enzyme activity.  Results from this 
experiment are shown in Figure 13, and varied enzyme concentrations from 0.0 
to 10.0 µg/mL.  Each reaction was allotted an incubation time of ten minutes.  A 
linear trend was established for this data set, with a R2 value of 0.9999.  It was 
decided to use an enzyme volume of 2.5 µL for each CYP1A2 assay. 
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Figure 13.  Results for Variation of Enzyme Concentration Using the CYP1A2 
Isoform. 
 
 
3.2.0 Bioassay – Guided Fractionation of Aҫai Berry 
 
 Initial fractionation of the aҫai berry, which is summarized in scheme 1, 
produced four crude extracts that were tested in CYP450 assays.  These crude 
extracts were tested in CYP1A1 and CYP1A2 enzyme reactions, as described in 
the Materials and Methods section.  Observed results were as follows: 
3.2.1 CYP1A2 versus Crude Aҫai Berry Extracts 
 The four initial, crude extracts were assayed in enzymatic reactions using 
CYP1A2 enzymes.  Crude aqueous, butanol, hexane, and chloroform extracts 
were screened in bioassays utilizing the 1A2 isoform.  Extracts were each 
evaluated at varied dosages of 10, 25, 50, and 100 μg/mL, to examine possible 
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interactions between an extract and the enzyme.  Collected data from screening 
CYP1A2 in the presence of the crude aҫai berry extracts can be found below in 
Figure 14. 
 When the aqueous extract was tested in CYP1A2 enzyme reaction, 
minimal inhibition was observed.  At concentrations of 10 and 25 μg/mL there 
was no inhibition observed.  At an increased concentration of 50 μg/mL an 
inhibition value of 2.71% was observed, and at an extremely high concentration 
of 100 μg/mL a slightly more modest value of 29.2% was observed. 
 An assay was performed to examine the effect of the crude butanol extract 
on CYP1A2 activity.  This extract showed no inhibitory effect on CYP1A2 at 
concentrations of 10, 25, and 50 μg/mL.  Even when tested at a concentration of 
100 μg/mL, only an inhibition value of 12.5% was observed. 
 Surprisingly, when the crude chloroform extract, which was hypothesized 
to exert the most potent inhibitory effects, was tested in CYP1A2 enzymatic 
assays, little effect was observed.  At extract concentrations of 10, 25, and 50 
μg/mL, there was no inhibition observed.  An inhibition value of 20.4% was 
reported when the extract was assayed at 100 μg/mL. 
 Of all the crude extracts evaluated in regards to CYP1A2 activity, the 
hexane extract proved to show the most potent inhibitory effect.  Although at a 
concentration of 10 μg/mL there was no observed inhibition, at a concentration of 
25 μg/mL an inhibition value of 8.27% was shown, at a concentration of 50 
μg/mL a value of 50.2% was shown, and at a concentration of 100 μg/mL a value 
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of 96.0% was shown.  From the data collected from this bioassay, an IC50 value 
between 49.0 – 50.0 μg/mL can be estimated for the hexane extract.  Despite the 
hexane extract proving to be the most potent inhibitor for the CYP1A2 isoform, 
chromatographic separation of lipid-like molecules often collected from hexane 
extractions is usually very difficult.  For this reason the hexane extract was not 
further purified and examined. 
 Data collected from screening CYP1A2 against the crude aҫai berry 
extracts showed no inhibitory effect at the lowest tested dosage of 10 μg/mL for 
any of the extracts.  At a dosage of 25 μg/mL the hexane extract showed a weak 
inhibition value of 8.27%, and was the only extract to have any effect.  Only at 
the highest tested concentration of 100 μg/mL was inhibition observed for all 
extracts.  Because of the poor results gathered from CYP1A2 assays with the 
crude extracts, it was decided to discontinue work with this isoform, and shift the 
focus towards the related CYP1A1 isoform. 
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Figure 14.  Inhibitory Effect of Crude Aҫai Berry Extracts on CYP1A2. 
 
 
3.2.2 CYP1A1 versus Crude Aҫai Berry Extracts 
 
 Crude extracts that were tested in CYP1A2 reactions, were also tested in 
CYP1A1 reactions.  Dose dependent bioassays were performed with the crude 
aqueous, butanol, hexane, and chloroform extracts, at dosages of 10, 25, 50, 
and 200 μg/mL, unless otherwise stated.  Results gathered from examining the 
effects of the crude aҫai berry extracts on CYP1A1 may be seen below in Figure 
15. 
CYP1A1 enzymatic reactions were carried out in the presence of 
increasing dosages of the aqueous extract, and showed little inhibition.  
Observed inhibition was only 4.72% at 10 µg/mL, 3.92% at 25 µg/mL, 15.3% at 
50 µg/mL, and 40.6% at 200 µg/mL.  The low observed inhibition is most likely 
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due the fact that water soluble components of plants, such as some vitamins and 
other nutrients, rarely come into contact with the CYP450 enzymes.  Water 
soluble compounds that enter the body are usually taken up in the stomach to be 
used elsewhere in the body or are passed along to the intestinal tract for 
riddance from the body or further reabsorption5. 
 Reactions were performed using incremental dosages of the butanol 
extract.  Observed inhibitions were 31.5% at 10 µg/mL, 74.5% at 25 µg/mL, and 
88.6% at 50 µg/mL.  Reactions were also carried out using 200 µg/mL, but the 
generated data was not quantifiable due to positive interference from 
constituents in the butanol extract, which eluted at the same time.  Although a 
fairly high inhibition value was seen at high dosages, they are somewhat 
insignificant because these concentrations are much too high compared to what 
would be seen in a physiological system. 
 When reactions were tested in the presence of an increasing hexane 
extract concentration, observed inhibition was 51.4% at 10 µg/mL, 73.0% at 25 
µg/mL, 80.4% at 50 µg/mL, and 52.7% at 200 µg/mL.  At a dosage of 200 µg/mL 
the acquired inhibition value (52.7%), was lower than the value (80.4%) obtained 
at 50 µg/mL.  This may indicate a mode of non-competitive inhibition, a way in 
which the inhibiting component does not compete with the actual substrate (7-
ethoxycoumarin) for a place in the active site of the enzyme.  Despite displaying 
promising values of inhibition at lower extract concentrations, as well as 
interesting results at higher concentrations, the hexane extract was not further 
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separated.  This is because hexane is a nonpolar solvent and typically extracts 
lipid or lipid-like molecules, which can prove to be quite challenging to separate 
via preparative chromatography. 
As expected, the chloroform extract proved to be the most potent inhibitor 
at low concentrations.  According to the data obtained from a dose dependent 
bioassay examining the chloroform extract, inhibition values were 79.2% at 10 
µg/mL, 89.4% at 25 µg/mL, 94.8% at 50 µg/mL, and 97.9% at 200 µg/mL 
concentrations.  The collected data appears to demonstrate a sigmoidal curve, 
which is characteristic of testing inhibitors at incremental concentrations. 
 
 
 
Figure 15.  Inhibitory Effect of Crude Aҫai Berry Extracts on CYP1A1. 
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An assay was performed to evaluate kinetic parameters of the CYP1A1 
enzyme in the presence of the crude chloroform extract.  A Michealis – Menten 
plot of this data can be seen below in Figure 16.  This was accomplished by 
preparing reaction mixtures with varied substrate concentrations, containing 
either no inhibitor, or inhibitor kept at a constant concentration.  Observed 
enzyme activity, for both the inhibited and non – inhibited samples, was plotted 
versus its associated substrate concentration.  Using the Michealis – Menten 
model of enzyme kinetics, a curve was generated to fit both sets of collected 
data.  From these curves it was shown that in the presence of no inhibitor 
CYP1A1 enzymes had a Km of 18.9 ± 4.95 μM and a Vmax of 1150 AU.  In the 
presence of 2 μg/mL  of crude chloroform extract a Km of 49.6 ± 10.9 and a Vmax 
of 1148.0 AU, while increasing the inhibitor concentration to 5 μg/mL  results 
showed a Km of 69.6 ± 16.2 μM and a Vmax of 1778.2 AU.  Due to the apparent 
competitive nature of this inhibitor, the Vmax was set to a constant 1125 AU in the 
Michealis – Menten equation used to fit the data.  Using the equations mentioned 
previously in section 1.3.1, a Ki was calculated from results at both inhibitor 
concentrations.  At a 2 μg/mL inhibitor concentration the calculated Ki was 1.23 ± 
0.30 μg/mL, and at an inhibitor concentration of 5 μg/mL the resulting Ki was 1.86 
± 0.46 µg/mL. 
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Figure 16.  Michealis – Menten Plot of CYP1A1 in the Presence of Crude 
Chloroform Extract. 
 
 
3.2.3 The 34- and 38-Series Compounds 
 
 Fractionation of the chloroform extract yielded the samples deemed the 
34-series, which contained ten fractions, labeled from 34-1 to 34-10.  A graph 
depicting results from screening the 34-series at 20 μg/mL can be found directly 
below this paragraph in Figure 17.  When reactions were carried out using a 
concentration of 20 µg/mL of the specific fraction, inhibition values were 60.6% 
for 34-1, 58.8% for 34-2, 37.3% for 34-3, 23.6% for 34-4, 42.7% for 34-5, 37.5% 
for 34-6, 55.5% for 34-7, 73.3% for 34-8, 25.2% for 34-9, and 45.6% for 34-10.    
It was shown that among the 34-series that the 34-8 fraction displayed the most 
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potent inhibition at 73.3%, and the least potent inhibition was observed with the 
34-4 fraction at 23.6%.  The crude chloroform extract was also tested with this 
series and showed an inhibition value of 65.4%, which was slightly lower than the 
34-8 fraction.  Due to such high inhibition portrayed by the 34-8 fraction, this 
fraction was chosen for further separation. 
 
 
 
Scheme 3.  Fractionation of Chloroform Extract into the 34-series Fractions. 
   
51 
 
 
 
Figure 17.  Screening of the 34-series Fractions on CYP1A1. 
 
 
 The 34-8 fraction was separated into a new series termed the 38-series, 
which originally consisted of eight different fractions.  Fractionation of 34-8 
resulted in acquiring minimal amounts of samples 38-6, 38-7, and 38-8, which 
were re-pooled and subjected to the fractionation process again to yield the 86-
series mentioned later in this chapter, which can be found in Figure 26.  Results 
gathered from screening the 38-series at a 20 μg/mL is displayed below in Figure 
18.  Remaining samples in the 38-series were tested in enzyme reactions at 20 
µg/mL and displayed inhibition values of 63.7% for 38-1, 72.3% for 38-2, 78.0% 
for 38-3, 41.3% for 38-4, and 43.1% for 38-5.  Fraction 38-3 showed slightly 
higher inhibition than its parent fraction 34-8, which was screened alongside the 
38-series in the same assay and showed an inhibition value of 76.3%.  Although 
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fraction 38-1 (63.7%), and 38-2 (72.3%), showed slightly lower inhibition values 
than their parent fraction 34-8, assays were further conducted containing their 
subsequently fractionated series.  Separation of 38-1 yielded the 61-series, while 
38-2 yielded the 62-series, and 38-3 yielded the 63-series.  Data collected from 
screening these series at 20 µg/mL showed a similar pattern as to what was 
observed from screening the 38-series, with many individual fractions displaying 
inhibition values greater than 50%. 
 
 
 
Scheme 4.  Generation of the 38-series Fractions from Parent Fraction 34-08. 
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Figure 18.  Screening of the 38-series Fractions on CYP1A1. 
 
 
It was also decided at this point to approach this project using three 
different variations of bioassay – guided screening.  The first approach involved 
testing a series of later stage fractions, the 97-series, which had been already 
separated for previous projects using different isoforms.  If inhibition was 
observed in the 97-series, it was also of interest to trace the inhibition back to the 
62-series.  Second, it was of interest to test the 86-series fractions as the parent 
fractions 38-6,7,8 had not been previously screened.  Continuation of the original 
bioassay – guided fractionation scheme at lower, more significant concentrations 
was the final approach. 
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3.2.4 Backtracking Inhibition from 97-Series Compounds 
 Another project tracking inhibition with the isoform CYP2E1, lead to the 
97-series fractions, which are subsequent fractionations of the 62-2 fraction.  It 
was also known that this series contained fractions consisting of pure 
compounds, which justified the deviation from the usual bioassay – guided 
approach.  To ensure that inhibition would be observed, this series was screened 
at relatively high concentrations.  A graph containing data from the 97-series 
assay is shown in Figure 19.  When screened at a concentration of 20 μg/mL the 
inhibition value was 73.2% for 97-A, was 70.2% for 97-B, was 73.1% for 97-C, 
was 71.6% for 97-D, was 74.8% for 97-E, was 61.1% for 97-F, was 61.7% for 97-
G, was 65.0% for 97-H, and was 68.0% for 97-I. 
 
 
 
Scheme 5.  Backtracking of the 97-series Fractions to Fraction 38-2.  
Fraction 38-2 is a crude fraction in which the 97-series was originally 
contained. 
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Figure 19.  Screening of the 97-series Fractions on CYP1A1. 
 
 
Fractions 97-B and 97-D were largely a single compound, and these 
fractions were further purified for identification by collaborators in the Oberlies 
laboratory.  Structure elucidation of these fractions showed that both were 
phaeophorbide molecules, and differed in the alkylation of an ester moiety.  
Figures 20 and 22 show the elucidated structures of fractions 97-B and 97-D.  It 
was of interest to test the dose-dependent effect of both of these fractions.  
Results observed from assaying CYP1A1 in incremental amounts of fractions 97-
B can be seen below in Figure 21, while directly below in Figure 23 data from 97-
D is shown.  Both fractions were tested at incremental doses of 1, 5, 10, and 20 
μg/mL.  Observed results for 97-B at 1 μg/mL was 26.3%, at 5 μg/mL was 59.4%, 
at 10 μg/mL was 67.0%, and at 20 μg/mL was 74.2%; while for 97-D at 1 μg/mL 
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was 31.8%, at 5 μg/mL was 61.1%, at 10 μg/mL was 69.8, and at 20 μg/mL was 
73.2%.  Although inhibition values observed from both fractions at doses of 5, 10, 
and 20 μg/mL appear rather high, they are not very significant, as both fractions 
are relatively pure and a bioavailability at these concentrations in a physiological 
system is not attainable.  More interest is focus on results gathered at a dose of 1 
μg/mL, as even though it is still rather high for a physiological setting, it is still a 
more realistic concentration.  Inhibition values of 26.3% for 97-B and 31.8% for 
97-D, indicate that these phaeophorbide molecules are a slightly mild inhibitor of 
CYP1A1. 
 
 
 
Figure 20.  Elucidated Structure of Fraction 97-B.  It was found to be a 
phaeophorbide molecule containing a methyl ester at the 3’’ position. 
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Figure 21.  Effect of Incremental Concentrations of Fraction 97-B on 
CYP1A1. 
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Figure 22.  Elucidated Structure of Fraction 97-D.  It was found to be a 
phaeophorbide molecule containing an ethyl ester at the 3’’ position. 
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Figure 23.  Effect of Incremental Concentrations of Fraction 97-D on CYP1A1. 
 
 
 Fraction 78-H was used to generate the 97-series fractions, so the entire 
78-series was screened at a concentration of 10 µg/mL.  This dosage was 
decreased from assays screened with the 97-series, as this was effort to 
preserve the bioassay – guided fractionation strategy.  A graph displaying this 
data can be seen below in Figure 24.  When tested at this concentration it was 
shown that 78-A showed an inhibition value of 74.7%, 78-B showed 58.2%, 78-C 
showed 66.0%, 78-D showed 73.3%, 78-E showed 71.1%, 78-F showed 29.1%, 
78-G showed 55.2%, 78-H showed 60.8%, and 78-Q showed 40.7%. 
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Scheme 6.  Backtracking the 97-series Fractions to Parent Fraction 78-H. 
 
 
 
 
Figure 24.  Screening of the 78-series Fractions on CYP1A1. 
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The 62-series had been previously screened at a concentration of 20 
μg/mL as mentioned in section 3.2.2 above, which proved to have little effect on 
CYP1A1.  A graph containing this data can be seen below in Figure 25.  
Inhibition values observed from screening the 62-series fractions at 20 μg/mL 
were 11.7% for 62-1, 38.1% for 62-2, 74.7% for 62-3, 69.2% for 62-4, and 62.7% 
for 62-5.  Fraction 62-2 was the parent fraction of the 78-series and showed a 
low inhibition value of 38.1% when tested at 20 µg/mL.  Compared to the parent 
fraction 38-2, which was screened alongside the 62-series fractions and gave an 
inhibition value of 67.8%, only fractions 62-3 and 62-4 demonstrated more potent 
inhibition.  These fractions were not further investigated, and the reasoning for 
this is explained in the later section 3.2.5.  Although fairly prominent inhibition 
was observed throughout the 97-series, it was tested at such a high 
concentration that it is not physiologically relevant.  It is also known that the 
CYP450 family will catalyze a wide breadth of substrates and that screening at 
such a high concentration of a pure compound can induce competitive inhibition 
naturally. 
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Scheme 7.  Backtracking the 78-series Fractions to Parent Fraction 62-2. 
 
 
 
 
Figure 25.  Screening of the 62-series Fractions on CYP1A1. 
   
62 
 
3.2.5 The 86-Series Compounds 
Due to the fraction 38-6/7/8 being unavailable at the time the rest of the 
38-series was screened, it was of interest to screen that fraction along with its 
subsequent fractionations the 86-series.  Because fraction 38-6/7/8 was not 
tested prior to the 86-series screening, it was unknown whether this series would 
have any inhibitory effect.  It had been observed in prior assays using more 
purified compounds that a concentration of 20 μg/mL was much too high, so in 
effort to negate the chances of observing false inhibition the dosage was dropped 
to 10 µg/mL.  Below in Figure 26 a graph containing data from the 86-series 
assay is shown.  When tested at this dosage fraction 38-6/7/8 displayed an 
inhibition value of 73.2%, 86-1 displayed 0.00%, 86-2 displayed 32.8%, 86-3 
displayed 72.2%, 86-4 displayed 62.5%, 86-5 displayed 75.0%, 86-6 displayed 
49.2%, and 86-7 displayed 0.00%.  Despite dropping the inhibitor concentrations 
down, it was still difficult to determine which fractions truly had the greatest 
inhibitory effect.  It was decided that the 38-series fractions would be tested at 
much lower doses, in an attempt to differentiate potent inhibition. 
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Scheme 8.  Generation of the 86-series Fractions from Parent Fraction 38-6/7/8. 
 
 
 
 
Figure 26.  Screening of the 86-series Fractions on CYP1A1. 
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3.2.6 Revisiting 38-Series Compounds and Subsequent Fractions 
 In an effort to identify the chief constituent contained within the crude 
chloroform extract responsible for the potent CYP1A1 enzyme inhibition, the 38-
series fractions were screened at a concentration of 0.5 μg/mL and 1.0 µg/mL.  
Figure 27 shown below, compares data collected from assaying the 38-series 
fractions at concentrations of 0.5 μg/mL, 1.0 μg/mL, and 20 µg/mL.  The 
observed trend that most fractions displayed apparent inhibition when tested at 
higher concentrations first arose when testing the 38-series fractions.  Recalling 
from the data collected from the 34-series fraction screening at 20 μg/mL, 
fraction 34-8 was by far the greatest inhibitor and was separated into the 38-
series fractions.  Results gathered from screening the 38-series at 20 μg/mL 
showed that fractions 38-4 and 38-5 had little effect on the 1A1 enzyme, and 
were not included in the screening at lower concentrations.  Also since screening 
fraction 38-6/7/8 and its subsequent 86-series fractions generated questionable 
results, fraction 38-6/7/8 was included in the assay. 
 Upon screening at a concentration of 1.0 μg/mL, it was observed that 
fraction 38-1 showed an inhibition value of 47.4%, fraction 38-2 showed 16.1%, 
fraction 38-3 showed 46.2%, and the pooled fraction 38-6/7/8 showed 25.7%.  
When compared to the parent fraction 34-8, which displayed an inhibition value 
of 33.5%, only fractions 38-1 and 38-3 showed a noticeably increased effect.  
However, results gathered from fraction 38-3 have a standard deviation of ±3.11 
AU and a calculated p – value of 0.0098, while results from 38-1 show a standard 
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deviation of ±8.10 AU and a calculated p – value of >0.05.  When the dosage 
was dropped to half of what was described previously, 0.5 μg/mL, an inhibition 
value of 14.1% was observed for fraction 38-1, 22.2% for fraction 38-2, 31.8% for 
38-3, and 23.1% for 38-6/7/8.  The parent fraction 34-8 showed a value of 25.1%, 
which was only outperformed by fraction 38-3.  Data collected from screening 
with 38-3 showed a standard deviation of ±1.16 AU and a calculated p – value 
<0.05.  It was determined at this point to proceed with screenings of the 61-series 
and 63-series fractions using the lowered concentrations as mentioned within this 
section. 
 
 
 
Scheme 9.  Generation of the 38-series Fractions from Parent Fraction 34-08. 
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Figure 27.  Screening of the 38-series Fractions at Lower Concentrations on 
CYP1A1. 
 
 
 Although data collected from samples containing fraction 38-1 showed 
poor inhibition when tested at a concentration of 0.5 μg/mL, it was the only other 
sample that showed comparable inhibition to fraction 38-3 at a concentration of 
1.0 μg/mL, despite the questionable statistics.  Also, subsequent fractionations of 
38-2 had been tested as a separate piece of this project, which showed relatively 
low inhibition for the concentration at which they had been tested at; further 
experiments regarding the 86-series, separated from the fraction 38-6/7/8, were 
not pursued as data collected from the 38-series screenings showed a stagnated 
inhibition value around 25%. 
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A graph comparing the data collected from 61-series screening at 0.5, 1.0, 
and 20 μg/mL can be found below in Figure 28.  When assays were performed to 
screen the 61-series fractions in the presence of 1.0 μg/mL  of the fractionated 
extract, observed inhibition for fraction 61-1 was 4.47%, fraction 61-2 was 4.27%, 
fraction 61-3 was 14.1%, fraction 61-4 was 28.4%, 61-5 was 19.7%, fraction 61-6 
was 25.4%, and the chromatograms generated from 61-7 assays were 
uninterpretable.  At a tested concentration of 0.5 μg/mL, fraction 61-1 showed an 
inhibition value of 1.07%, 61-2 showed 3.39%, 61-3 showed 0.36%, 61-4 showed 
12.4%, 61-5 showed 14.1%, 61-6 showed 8.73%, and 61-7 showed 6.47%.  It 
was also shown that data collected during the screening of 38-1 mentioned 
earlier, was indeed an artifact, as the parent fraction 38-1 showed an inhibition 
value of 5.95% at 0.5 μg/mL and only 11.9% at 1.0 µg/mL.  Due to the rather 
poor inhibition observed from screening the 61-series, further investigated was 
not pursued. 
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Scheme 10.  Generation of the 61-series Fractions from Parent Fraction 38-1. 
 
 
 
 
Figure 28.  Screening of the 61-series Fractions on CYP1A1. 
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 As indicated by data gathered from the 38-series screenings at low 
concentrations, fraction 38-3 appeared to contain a constituent that was majorly 
responsible for the inhibition observed in the chloroform extract, although not 
entirely.  Initially, prior to the deviation of the activity guided fractionation scheme, 
the 63-series fractions had been tested at concentrations of 20, 10, and 5 µg/mL.  
Data collected from these experiments showed the majority of the tested 
fractions displayed inhibition values greater than 50%, however, the parent 
compound 38-3 showed the greatest inhibitory effect of all testes fractions.  
These assays had not included fraction 63-4 in the experiments due to 
unavailability at the time.  Upon the screening of the 63-series at low 
concentrations, fraction 63-4 had been reacquired and was used in the 
experiments.  Data gathered pertaining to experiments gathered at tested 
concentrations of 20, 10, 5.0, 1.0, and 0.5 μg/mL of the 63-series fractions can 
be seen below in Figure 29.  At a concentration of 1 μg/mL, fraction 63-1 showed 
an inhibition value of 5.41%, 63-2 showed 19.3%, 63-3 showed 22.3%, 63-4 
showed 36.9%, 63-5 showed 10.2%, and 63-6 showed 3.74%.  Upon comparison 
of the parent fraction 38-3, which displayed an inhibitory effect of 27.1%, only 
results collected from fraction 63-4 gave a larger inhibition value, and had a 
standard deviation of ±1.12 and a calculated p – value of <0.01.  To confirm the 
claim that fraction 63-4 was a potent inhibitor, the concentration present was 
dropped to 0.5 µg/mL.  When tested at this dosage, fraction 63-1 resulted in an 
inhibition value of 3.90%, 63-2 resulted in a value of 6.13%, 63-3 resulted in a 
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value of 10.3%, 63-4 resulted in a value of 21.7%, 63-5 resulted in a value of 
12.8%, and 63-6 resulted in a value of 12.9%.  Once again fraction 63-4, which 
showed a standard deviation of ±1.90 and a calculated p-value of <0.05, was the 
only fraction to exert a more potent effect than the parent fraction 38-3, which 
showed a value of 14.5%. 
 
 
 
Scheme 11.  Generation of the 63-series Fractions from Parent Fraction 38-3. 
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Figure 29.  Screening of the 63-series Fractions on CYP1A1. 
 
 
3.2.7 The 94-Series Compounds 
 Fraction 63-4 was separated into the 94-series fractions, whose individual 
fractions were relatively pure samples.  Observation of fractions exerting a highly 
inhibitory effect would warrant purification of the fraction, and elucidation of its 
chemical structure.  Data collected from screening the 94-series fractions can be 
found below in Figure 30.  This series was also tested at the lowered 
concentrations of 1.0 μg/mL and 0.5 μg/mL, as it had been observed that there 
are many constituents within the aҫai berry extract that inhibit CYP1A1 at 
increased concentrations.  Assays using a dosage of 1.0 μg/mL resulted in 
22.7% inhibition for 94-A, in 20.4% inhibition for 94-B, in inhibition 73.4% for 94-
C, in 57.1% inhibition for 94-E, in 27.2% inhibition for 94-F, in 45.6% inhibition for 
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94-G, in 19.8% inhibition for 94-H, and in 22.1% inhibition for 94-I.  Upon 
comparison to the parent fraction 63-4, which gave an inhibition value of 40.6% 
in the presence of 1.0 μg/mL, fractions 94-C, 94-D, and 94-G showed an 
increased inhibitory effect.  When tested at a concentration of 0.5 μg/mL, results 
were shown to be 18.7% for 94-A, 4.12% for 94-B, 41.9% for 94-C, 32.7% for 94-
D, 7.57% for 94-E, 6.92% for 94-F, 25.8% for 94-G, 9.12% for 94-H, and 8.59% 
for 94-I.  At this concentration the parent fraction resulted in an inhibition value of 
18.7%, which was again surpassed by fractions 94-C, 94-D, and 94-G.  By far, 
fractions 94-C and D displayed the most potent inhibition, but the inhibition 
observed from testing 94-D is believed to be caused by the same constituent 
found in fraction 94-C.  This is a common effect resulting from the process of 
preparative liquid chromatography.  results gathered from enzyme reactions in 
the presence of 1.0 μg/mL  fraction 94-C gave a standard deviation of ± 0.018% 
and a calculated p-value of < 0.001, while data collected at the lowered dosage 
of 0.5 μg/mL  showed a resulting standard deviation of ± 0.79% and a calculated 
p-value of < 0.05.  Data collected from screening fraction 94-G at 1.0 μg/mL 
displayed a standard deviation of ± 0.23% and a calculated p-value of < 0.001, 
and at a dosage of 0.5 μg/mL showed a standard deviation of ± 5.99% and a 
calculated p-value of > 0.05.  Due to the lesser potency of fraction 94-G, as well 
as the less significant data collected at 0.5 μg/mL, it was decided to pursue 
structure elucidation with fraction 94-C. 
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Scheme 12.  Generation of the 94-series Fractions from Parent Fraction 63-4. 
 
 
 
 
Figure 30.  Screening of the 94-series Fractions on CYP1A1. 
   
74 
 
3.3.0 Structure Elucidation of Fraction 94-C 
 Structure elucidation of fraction 94-C was carried out by the Oberlies’ 
laboratory, the collaborating group in this project.  Using a variety of nuclear 
magnetic resonance applications, in particular 1H-NMR, 13C-NMR, COSY, 
HSQC, and HMBC, data were collected to determine the structure of the 
constituent found in fraction 94-C, which is listed in Figure 31.  The molecule 
responsible for the potent inhibition of CYP1A1 was found to be 5,7,3’-trihydroxy-
4’-methoxyflavone, which is more commonly referred to as diosmetin.  Diosmetin 
belongs to the large family termed the polyphenols, but is more specifically 
identified as a flavone.  The structure of diosmetin can be seen above the 
generated NMR data. 
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Figure 31.  NMR Data Pertaining to the Structure of Fraction 94-C.  Data was 
collected by collaborators from the Oberlies’ group, and was found to be 5,7,3’-
trihydroxy-4’-methoxyflavone (shown above chart as “diosmetin”). 
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3.3.1 Comparison of Fraction 94-C and Diosmetin 
 In order to show that diosmetin was indeed the molecule found in fraction 
94-C that was responsible for CYP1A1 inhibition, crystalline diosmetin was 
purchased to compare its effect to fraction 94-C.  A substrate dependent assay 
was used to generate a Michaelis – Menten plot, which could then be interpreted 
to find a Ki value.  Comparison of these Ki values generated by the purchased 
diosmetin and fraction 94-C, should bear similar results, which would confirm the 
statement that diosmetin is a very potent inhibitor of CYP1A1. 
 An experiment was performed varying substrate concentrations from 0.0 
μM to 250 μM in the presence of 0.0 μg/mL fraction 94-C, 0.5 μg/mL fraction 94-
C, and 1.0 μg/mL 94-C.  A Michealis – Menten plot from this experiment can be 
found in Figure 32.  Results show a Km of 21.7 ± 7.00 μM and a VMax of 1110 AU 
for the controlled reaction.  In the presence of 1.0 μg/mL  fraction 94-C an 
apparent Km of 74.6 ± 9.29 μM and VMax of 2470 AU were determined, while in 
the presence of 0.5 ng/mL fraction 94-C a Km of 102.5 ± 23.1 μM and VMax of 
1000 AU were determined.  Because a decreasing effect was not observed on 
the VMax, this variable was set to a constant 1250 AU for each data set.  It was 
found that in the presence of 1.0 μg/mL fraction 94-C the Ki was 0.42 ± 0.09 
μg/mL, and at the lower 0.5 μg/mL dosage the Ki was 0.13 ± 0.04 µg/mL. 
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Figure 32.  Michealis – Menten Plot of CYP1A1 in the Presence of Fraction 94-C. 
 
 
 A similar assay was performed with the CYP1A1 isoform using a 
purchased diosmetin standard, rather than the fractionated sample 94-C.  
Results from this experiment can be found in Figure 33.  Substrate 
concentrations were varied from 0.0 to 250.0 μM in the presence of 0.0 ng/mL 
diosmetin, 100 ng/mL diosmetin, and 500 ng/mL diosmetin.  From the controlled 
samples a Km of 42.4 ± 19.9 μM and a Vmax of 1291.0 AU were determined.  
While in the presence of 500 ng/mL diosmetin a Km of 93.8 ± 46.5 μM and a Vmax 
of 1139.9 AU were determined, while in the presence of 100 ng/mL diosmetin a 
Km of 82.2 ± 48.0 μM and a Vmax of 1244.2 AU were determined.  Using this 
information a Ki for the 500 ng/mL reactions was found to be 412 ± 199 ng/mL, 
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and in the 100 ng/mL reactions a Ki of 106 ± 55.8 ng/mL was calculated.  Results 
gathered from the use of the purchased diosmetin standard show similar 
calculated Ki values compared to the data gathered with fraction 94-C.  However, 
this was expected as the fraction 94-C was relatively pure, and these results 
confirm that diosmetin is the constituent responsible for inhibition. 
 
 
 
Figure 33.  Michealis – Menten Plot of CYP1A1 Activity in the Presence of 
Purchased Diosmetin. 
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CHAPTER IV 
 
CONCLUSION 
 
 
 In the presence of the initial, four, crude extracts of acai berry, CYP1A2 
showed no apparent inhibition, even at very high dosages.  It is important to 
investigate possible interactions with the CYP1A2 isoform, as the number of its 
pharmaceutical substrates has increased largely over the past decade.  Results 
are indicative that concomitant intake of a pharmaceutical metabolized by 
CYP1A2 and aҫai berry should have no potential pharmacokinetic interactions 
and may be deemed as safe. 
 It was also shown that the Chloroform extract had an extremely potent 
inhibitory effect on CYP1A1 enzyme reactions.  Initial screening of the crude 
chloroform extract with CYP1A1 showed a remarkable 79.2% inhibition, when 
tested at the lowest dosage of 10 µg/mL.  The chloroform extract was subjected 
to several rounds of inhibition-directed based fractionations.  Shown below in 
scheme 12 is a detailed summary of the results from screening aҫai berry 
extracts, which shows the inhibitory effect observed on CYP1A1 O-deethylation 
of 7-ethoxycoumarin. 
 
 
 
 
 
Scheme 13. Bioassay Guided Fractionation Diagram Depicting Results from CYP1A1 Isoform Screenings.  Diagram 
shows the observed inhibition seen in CYP1A1 catalyzed 7-ethoxycoumarin deethylation reaction 
while in the presence of açai berry fractions.
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 Because fractions 38-1, 38-2, 38-3, and 38-6/7/8 displayed modest 
inhibition when tested at dosages ranging from 10 – 20 μg/mL, it can be said that 
many constituents contained within the chloroform extract are inhibitors of 
CYP1A1 at high concentrations.  However, when tested concentrations were 
lowered to more physiological relevant levels (500 ng/mL and 1 µg/mL), only 
fraction 38-3 displayed modest inhibition.  Subsequent fractionations of 38-3 
revealed that fraction 94-C contained the primary constituent responsible for the 
observed inhibition.  Structure elucidation found that 5,7,3’-trihydroxy-4’-
methoxyflavone, more commonly known as diosmetin, was the major compound 
in fraction 94-C.  Diosmetin is a methoxylated flavone, a class of flavonoid 
molecules that has recently shown promise in affecting cancinogenesis.  Studies 
investigating 5,7-dimethoxyflavone’s effect on CYP1A1 showed that this 
methoxylated flavone exerted a potent effect at 1 – 2 μM concentrations58.  
However, results found in this project show that the cruder fraction 94-C has a Ki 
of 0.327 μg/mL at a dosage of 1.0 μg/mL 94-C and 0.243 μg/mL at 0.5 μg/mL, 
while the purchased standard of diosmetin gave an observed Ki of 9.23 ng/mL at 
a concentration of 500 ng/mL and 2.51 ng/mL at a 100 ng/mL concentration. 
A previous study conducted by Ciolino et al. in 1998, also found diosmetin 
to be a potent inhibitor of CYP1A173.  Results from this study found an IC50 value 
of 30.0 nM using DMBA – induced CYP1A1 enzymes.  Although these are two 
different values used to evaluate enzyme inhibition, both values were found to be 
in the nanomolar range, which is consistent as to what was found in this study.  
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Inhibition of CYP1A1 enzymatic catalysis is quite important, as it is a means to 
decrease the bioactivation of carcinogen compounds within the body.  Past 
works evaluating the bioavailability of diosmetin after consumption, have shown 
serum plasma concentrations ranging from a few ng/mL to several hundred 
ng/mL following the same oral dosages of 400 – 600 mg diosmetin.  A more 
recent study using HPLC-MS/MS methodology reported that following 
consumption of diosmetin, its glucuronide form was detected and reached levels 
up to 10 ng/mL, however, concentrations of free diosmetin were below the 
detection limit of 50 pg/mL74.  Further work still is required to confirm and clarify 
this finding. 
 In summary, constituents within the aҫai berry appear to no effect on the 
CYP1A2 isoform, but have a much greater effect on its close relative CYP1A1.  
As CYP1A1 is not largely responsible for metabolism of pharmaceutical drugs, 
this suggests that concomitant intake of prescribed pharmaceuticals and aҫai 
berry appears safe.  Diosmetin has been shown to account for a small 
percentage of the total crude, aҫai, plant material, which would require the 
consumption of a considerable amount of aҫai berry to observe a 
chemopreventative effect.  Screening of aҫai berry extracts with other CYP450 
isoforms in this project has shown that only CYP2E1 was affected by diosmetin, 
and it appears to have some effect on cell culture modeling of the antioxidant 
response element pathway.  Current research is also evaluating the antioxidant 
effect of diosmetin in cell culture studies. 
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